PURETECH HEALTH PLC - ADR
PureTech Health plc is a healthcare company focused on scientific research and innovation.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying PureTech Health's stock, anticipating significant growth in value.
Financial Health
Puretech Health is generating minimal revenue, indicating potential challenges in its business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PRTC
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketOrphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketDigital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketDigital Therapeutics
Software that works like medicine. These companies are creating clinically validated digital tools that treat and manage diseases just like traditional pharmaceuticals, but with the scalability of technology. Professional investors see enormous potential in this rapidly evolving healthcare frontier.
Published: June 17, 2025
Explore BasketGarage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical‑stage catalysts
Trial results and regulatory milestones can cause meaningful share‑price moves; these events are worth monitoring, though outcomes can be binary and unpredictable.
Spin‑outs and deals
PureTech often incubates subsidiaries and pursues licensing or partnerships, which can unlock value but also make valuation more complex and dependent on external partners.
Volatile, long‑term play
As an ADR in early‑stage biotech, it may suit investors with a long horizon and higher risk tolerance; always weigh potential upside against possible significant losses.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
